RAPTT
RAPTT Corp
RAPT Therapeutics is a clinical-stage, immunology-focused biopharmaceutical company dedicated to developing oral small-molecule therapies. The company targets oncology and inflammatory diseases with significant unmet needs by creating treatments that modulate critical immune drivers.
Products & Team
Zelnecirnon (RPT193)
Zelnecirnon is an oral drug candidate developed to treat inflammatory diseases by selectively inhibiting the migration of type 2 T helper cells into inflamed tissues. It has been evaluated in clinical trials for atopic dermatitis and asthma; however, in February 2024, the FDA enacted a clinical hold on its trials following a reported case of liver failure in a patient.
It addresses the need for effective, convenient oral treatments for inflammatory conditions like atopic dermatitis by targeting a specific pathway of immune cell migration that drives the disease.
The company addresses significant unmet medical needs for patients who may lack effective therapies or prefer the convenience of an oral medication over injectable alternatives for chronic conditions.